Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01074450 · ClinicalTrials.gov registry record · Phase 1
Pramipexole Dihydrochloride 0.25 mg Tablets Under Fasting Conditions
A Phase 1 study, sponsored by Teva Pharmaceuticals USA.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT01074450: Completed Phase 1 study, sponsored by Teva Pharmaceuticals USA.
NCT01074450 is a Phase 1 study that has completed, run by Teva Pharmaceuticals USA. The registered enrollment target is 24 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01074450, a Phase 1 study, has completed, sponsored by Teva Pharmaceuticals USA.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The object of this study was to compare the relative bioavailability (rate and extent of absorption) of Pramipexole Dihydrochloride Tablets 0.25 mg by Barr Laboratories, Inc. with that of Mirapex® Tablets 0.25 mg distributed by Boehringer Ingelheim Pharmaceuticals, Inc. following a single oral dose in healthy adults under fasting conditions.
Interventions
- DRUG Pramipexole Dihydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2005-02 |
| Est. Completion | 2005-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01074450
The ClinicalTrials.gov registry entry for NCT01074450 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teva Pharmaceuticals USA, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pramipexole Dihydrochloride is the first listed.
NCT01074450 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01074450 about?
NCT01074450 is a clinical study titled "Pramipexole Dihydrochloride 0.25 mg Tablets Under Fasting Conditions". The object of this study was to compare the relative bioavailability (rate and extent of absorption) of Pramipexole Dihydrochloride Tablets 0.25 mg by Barr Laboratories, Inc. with that of Mirapex® Tablets 0.25 mg distributed by Boehringer Ingelheim Pharmaceuticals, Inc. following a single oral dose ...
What is the current status of trial NCT01074450?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2005-02. Estimated completion is 2005-03.
What interventions are being tested in trial NCT01074450?
The interventions under investigation include: Pramipexole Dihydrochloride (DRUG).
Who is sponsoring clinical trial NCT01074450?
This trial is sponsored by Teva Pharmaceuticals USA, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.